#NRSN

9 hours ago

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity The Journal of the American Medical Association publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2 b trial in ALS, including slower functional decline, reduced risk of ALS-related complications, and modulation of disease-relevant biomarkers. CAMBRIDGE, Mass., March 16, 2026/ PRNewswire/-- NeuroSense...

#NRSN #NRSNW JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

www.stocktitan.net/news/NRSN/jama-neurology...

0 0 0 0

StockTitan

@stocktitan.net

1 week ago

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference NeuroSense (NASDAQ: NRSN) will present long-term survival data from the Phase 2b PARADIGM trial of PrimeC at the MDA Clinical & Scientific Conference on March 9, 2026. The analysis showed a 65% reduction in risk of death (HR 0.35; p=0.0037) and a >14-month median survival benefit (36.3 vs. 21.4 months; log-rank p=0.0218).The randomized, double-blind, placebo-controlled study enrolled 68 participants (2:1 randomization) with a six-month double-blind period followed by an open-label extension; safety was described as favorable.

#NRSN #NRSNW PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

www.stocktitan.net/news/NRSN/prime-c-long-t...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB NeuroSense (NASDAQ: NRSN) announced that Prof. Steven E. Arnold, a noted Alzheimer's expert and Professor of Neurology at Harvard Medical School, has joined its Scientific Advisory Board.The company said Prof. Arnold brings biomarker-driven clinical development and translational neuroscience experience as NeuroSense advances its PrimeC programs in ALS and Alzheimer's disease. NeuroSense reported that its proof-of-concept Alzheimer's study (RoAD) showed a favorable safety and tolerability profile, and that clinical and biomarker outcomes from RoAD are expected in Q1 2026.

#NRSN #NRSNW World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

www.stocktitan.net/news/NRSN/world-renowned...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study NeuroSense (NASDAQ: NRSN) reported completion of the safety analysis from its Phase 2 randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC in Alzheimer's disease on Dec 22, 2025.The safety review found a favorable tolerability profile, with no serious adverse events reported and no new or unexpected safety signals identified. Clinical outcome measures in this exploratory proof-of-concept study are descriptive by design.NeuroSense will analyze clinical observations together with biomarker data to aid interpretation, and full clinical and biomarker results are expected in Q1 2026.

#NRSN NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

www.stocktitan.net/news/NRSN/neuro-sense-co...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

#NRSN #NRSNW NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

www.stocktitan.net/news/NRSN/neuro-sense-to...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS NeuroSense (Nasdaq: NRSN) announced that the U.S. Food and Drug Administration completed review of its IND amendment and authorized initiation of the pivotal Phase 3 trial PARAGON evaluating PrimeC in amyotrophic lateral sclerosis (ALS) on Nov 24, 2025. PARAGON is planned as a global, double-blind, 12-month, placebo-controlled study with 300 participants randomized 2:1 (PrimeC:placebo), an open-label extension, an adaptive design with interim analyses, and is powered at >95% for its primary endpoint. NeuroSense aims to enroll the first patient in the coming months subject to securing strategic resources. Additional trial details and timelines will be presented at an investor webinar on Dec 8, 2025.

#NRSN NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

www.stocktitan.net/news/NRSN/neuro-sense-re...

0 0 0 0

Oninvest

@oninvest.bsky.social

4 months ago

Noble initiates on ALS drugmaker NeuroSense with 'outperform', TP for 600% upside – Oninvest Noble Capital Markets has initiated coverage of NeuroSense Therapeutics with an “outperform” rating and a target price of $9 per share. Thus, it estimates the micro-cap developer of an amyotrophic lat...

🚀 Noble Capital Markets launched coverage on #NRSN with an Outperform and $9 target — a potential 620% upside. The call hinges on promising mid-stage data for its ALS drug #PrimeC, seen as a fast-track approval candidate. en.oninvest.com/article/nobl...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers NeuroSense (NASDAQ: NRSN) reported Phase‑2b plasma biomarker results for PrimeC on October 6, 2025 showing statistically significant reductions in multiple Alzheimer's‑linked microRNAs. Key measured reductions from baseline include miR‑21‑5p (p=0.003), miR‑146a‑5p (p=0.007), miR‑let‑7e‑5p (p=0.006) and miR‑let‑7a‑5p (p=0.028), while placebo showed no significant changes over time. The company said these miRNA changes reflect reduced neuroinflammatory and neurodegenerative activity and support PrimeC's potential as a disease‑modifying therapy. NeuroSense indicated the data will inform design of a follow‑on Alzheimer's study and that Phase‑3 readiness for PrimeC in ALS remains ongoing.

#NRSN NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

www.stocktitan.net/news/NRSN/neuro-sense-pr...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price NeuroSense Therapeutics (NASDAQ: NRSN), a late-clinical stage biotech company focused on neurodegenerative diseases, has secured a $500,000 private placement from a single investor. The company will issue 333,334 ordinary shares at $1.50 per share, representing a significant 40% premium to the September 3, 2025 closing price.The financing, expected to close on September 8, 2025, will provide working capital and serve as a bridge to upcoming milestones. CEO Alon Ben-Noon highlighted this as their third premium-to-market financing, emphasizing minimal shareholder dilution while strengthening the company's balance sheet.

#NRSN NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

www.stocktitan.net/news/NRSN/neuro-sense-th...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

NeuroSense Provides Business Update and Progress for the First Half of 2025 NeuroSense Therapeutics (NASDAQ: NRSN) provided a comprehensive business update for H1 2025, highlighting progress in its ALS treatment development. The company's lead candidate PrimeC showed promising Phase 2b results, with treatment slowing functional decline by ~40% and improving overall survival by 74% in the per-protocol population.Key developments include regaining Nasdaq compliance through a $5M private placement, advancing manufacturing capabilities to commercial scale, and preparing for a Phase 3 trial in H2 2025. The company reported reduced R&D expenses of $2.5M (down 32.9% YoY) and maintained stable G&A expenses at $2.2M.NeuroSense is pursuing regulatory pathways including a planned NOC/c submission in Canada and continues discussions for a potential global pharmaceutical partnership following a Q4 2024 binding term sheet.

#NRSN NeuroSense Provides Business Update and Progress for the First Half of 2025

www.stocktitan.net/news/NRSN/neuro-sense-pr...

0 0 0 0

Cecilie Nome

@cecilienome.bsky.social

8 months ago

Had a fantastic time at the NRSN/NORA.ai pre-meeting for the regional FENS meeting in Oslo last weekend! Honored to be part of the organizing team and thrilled to see everything come together at Tøyen Hovedgård. Huge thanks to all who contributed to the inspiring discussions! #FRM2025 #FENS #NRSN

2 0 0 0

StockTitan

@stocktitan.net

10 months ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch NeuroSense Therapeutics (NASDAQ: NRSN) has achieved a crucial milestone in its commercialization strategy by successfully scaling up the production of PrimeC, its potential ALS treatment, to commercial levels. The company has partnered with a global CDMO and implemented comprehensive CMC enhancements to ensure robust manufacturing infrastructure. Key achievements include:- Qualification of U.S. and Canadian DMF and CEP holders for APIs- Validation of analytical methods for drug product release and stability- Confirmation of 36-month room-temperature shelf life- Patent protection through 2042NeuroSense is pursuing early market entry in Canada through the NOC/c pathway, with projected peak annual revenue of $100-150 million in the Canadian market. This follows promising efficacy data from the Phase 2b PARADIGM study.

#NRSN NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

www.stocktitan.net/news/NRSN/neuro-sense-th...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update NeuroSense Therapeutics (NASDAQ: NRSN) has issued a shareholder letter highlighting significant developments in their ALS treatment program. The company's Phase 2b PARADIGM study for PrimeC showed promising results, demonstrating a 33% slowing of disease progression (p=0.007) and 58% improvement in survival rates compared to placebo.The company is preparing for a Phase 3 clinical trial in the second half of 2025, primarily across the US and Europe. In Canada, NeuroSense is pursuing early access through Health Canada's NOC/c pathway, with potential peak annual revenue of $100-150 million in that market.A binding term sheet signed with a global pharmaceutical company in December 2024 is still under negotiation. The partnership discussions, though taking longer than initially expected due to multi-regional complexity, remain active and constructive.

#NRSN NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

www.stocktitan.net/news/NRSN/neuro-sense-th...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% New Phase 2b data reveals PrimeC's breakthrough impact on ALS through microRNA modulation, demonstrating significant disease-slowing effects. Full analysis inside.

#NRSN NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

www.stocktitan.net/news/NRSN/neuro-sense-th...

1 0 0 0

StockTitan

@stocktitan.net

11 months ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates NeuroSense Therapeutics (NRSN) has reported significant clinical progress in 2024, with its lead drug PrimeC showing promising results in a Phase 2b ALS study. The trial demonstrated a 33% slowdown in disease progression (p=0.007) and a 58% improvement in survival rates after 18 months.The company has aligned Phase 3 study design with FDA and plans initiation in 2025. NeuroSense is pursuing partnership discussions for PrimeC's advancement and plans early commercialization in Canada, with estimated peak annual revenues of $100m-$150m.Financial results show R&D expenses decreased by 21.9% to $5.7M in 2024, while G&A expenses reduced by 12.5% to $4.2M. The company ended 2024 with $3.4M in cash and reported a net loss of $10.2M.

#NRSN NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

www.stocktitan.net/news/NRSN/neuro-sense-th...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

NeuroSense Secures Major Pharma Partnership for Breakthrough ALS Drug PrimeC Leading pharmaceutical company backs NeuroSense's PrimeC with substantial funding, milestone payments, and royalties. Phase 2b trial shows promising results for ALS treatment.

#NRSN NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

www.stocktitan.net/news/NRSN/neuro-sense-th...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #NRSN ) NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

#StockMarket #News

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

NeuroSense's ALS Drug Shows Breakthrough Results: 58% Better Survival Rate in Phase 2b Trial NeuroSense's PrimeC demonstrates remarkable efficacy in ALS treatment, with 33% slower disease progression in Phase 2b study. FDA backs Phase 3 plans amid promising data.

#NRSN NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

www.stocktitan.net/news/NRSN/neuro-sense-pr...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

NeuroSense's ALS Drug PrimeC Advances: FDA Green-Lights Phase 3 Design After Promising Trial Results NeuroSense receives FDA support for PrimeC Phase 3 trial design following strong Phase 2b results in ALS treatment. 300-patient study set to launch mid-2025.

#NRSN NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

#investing #StockMarket #news

www.stocktitan.net/news/NRSN/neuro-sense-re...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

NeuroSense's PrimeC Shows Breakthrough 58% Survival Boost in ALS Treatment Study | NRSN Stock News Groundbreaking results reveal PrimeC significantly slows ALS progression by 33% and improves survival rates by 58% in 18-month PARADIGM clinical study.

#NRSN NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

#StockMarket #investing #news

www.stocktitan.net/news/NRSN/neuro-sense-an...